Physician profile
Jared Michael Gorter
NPI 1972212892
$5,421.17
in general payments reported to CMS, 2019-2025
27 companies · $2,271 in 2025
The $2,271 reported for 2025 was more than what 94% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.89 · 2023: $790 · 2024: $2,342 · 2025: $2,271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,996 · Education: $407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,995.97 |
| Education | $407.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $711.84 | 2023-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $696.43 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $644.14 | 2023-2025 | Sotyktu |
| Amgen INC. | $455.09 | 2023-2025 | Otezla, Otezla |
| Abbvie INC. | $417.64 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $324.60 | 2023-2025 | Ilumya, Winlevi |
| Janssen Biotech, INC. | $320.52 | 2024-2025 | Tremfya |
| Dermavant Sciences, INC. | $306.39 | 2024 | Vtama |
| Leo Pharma INC. | $269.57 | 2023-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $264.09 | 2023-2025 | |
| Ucb, INC. | $152.19 | 2023-2025 | Bimzelx |
| Novartis Pharmaceuticals Corporation | $146.16 | 2023-2025 | |
| Lilly USA, LLC | $106.84 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Incyte Corporation | $104.46 | 2025 | Opzelura |
| Verrica Pharmaceuticals INC. | $84.85 | 2023-2025 | Ycanth |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $77.91 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $60.62 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $44.98 | 2023-2025 | Nemluvio |
| Pfizer INC. | $42.12 | 2025 | |
| Paratek Pharmaceuticals, INC. | $27.25 | 2025 | Nuzyra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.91 | 2024 | Spevigo |
| Merz North America, INC. | $26.38 | 2024 | |
| Medtronic, INC. | $24.31 | 2025 | Venaseal |
| Mimedx Group, INC. | $23.92 | 2025 | |
| Blueprint Medicines Corporation | $21.36 | 2024 | Ayvakit |
| Organogenesis INC. | $21.30 | 2025 | Puraply Wound Matrix |
| Medimetriks Pharmaceuticals, INC. | $19.30 | 2025 | Genadur |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Gorter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.